TAAR8A activators represent a chemical class of compounds that interact with the trace amine-associated receptor 8A, a G protein-coupled receptor (GPCR). This receptor, like others in the TAAR family, is believed to respond to small molecule ligands, traditionally amines, and to engage in signaling cascades that regulate various physiological processes. The activation of TAAR8A involves the binding of an agonist to the receptor, which triggers a conformational change, allowing the receptor to couple with intracellular G proteins. This coupling initiates a signaling cascade, often resulting in the production of second messengers such as cyclic AMP (cAMP), which further propagates the signal within the cell.
The class of TAAR8A activators includes compounds that are capable of increasing the receptor's activity either directly or by influencing related cellular mechanisms. For instance, certain activators may increase intracellular cAMP levels, either by stimulating adenylate cyclase or by inhibiting the breakdown of cAMP via phosphodiesterases, which in turn can enhance the receptor's signaling. Other members of this class can modulate the activity of TAAR8A by altering the levels or activity of neurotransmitters that affect GPCR signaling pathways. Additionally, some compounds can influence the receptor indirectly by altering the signaling environment in which TAAR8A operates, such as by affecting other GPCRs that may have crosstalk with TAAR8A. Activation of TAAR8A by these activators influences intracellular signaling pathways and can modify cellular responses, making the understanding of these compounds and their interactions with TAAR8A an area of interest in the study of GPCR signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Inhibits phosphodiesterases, preventing cAMP breakdown, thus sustaining GPCR signaling that could possibly activate TAAR8A via cAMP-dependent pathways. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
As a neurotransmitter and hormone, it can modulate GPCR function and could possibly activate TAAR8A through interactions with sympathetic nervous system pathways. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Acts on its own GPCRs but also modulates other GPCR signaling; could possibly activate TAAR8A through histaminergic pathway interactions. | ||||||
Levodopa | 59-92-7 | sc-205372 sc-205372A | 5 g 25 g | $54.00 $171.00 | 9 | |
As a precursor to dopamine, it can increase dopamine levels, which could possibly activate TAAR8A via altered neurotransmission. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
An adenosine receptor antagonist that increases cAMP by preventing the inhibitory effect of adenosine on adenylate cyclase, potentially affecting TAAR8A signaling through cAMP-dependent pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
A selective inhibitor of phosphodiesterase 4 that raises cAMP levels in the central nervous system, which could possibly activate TAAR8A if linked to cAMP pathways. | ||||||